Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019
Homology Medicines, Inc. (FIXX)
Last homology medicines, inc. earnings: 3/12 04:10 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
- Two Additional Programs Advance to IND-Enabling Studies, Including First Gene Editing Program and a CNS Gene Therapy - - Homology’s New GMP Manufacturing Facility Preparing for Production at 500 Liter Scale - - Orphan Drug Designation Granted for HMI-102 PKU Gene Therapy in the U.S. and E.U. - BEDFORD, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced that it achieved all corporate goals for 2018, positioning the Company to start a Phase 1/2 clinical trial of the Company’s first gene therapy program in adults with phenylketonuria (PKU), with initial data expected in 2019. Homology closed out the year by nominating development candidates for two additional programs focused on pediatric rare genetic diseases, both of which have entered into IND-enabling studies. These candidates comprise a nuclease-free in vivo gene editing approach for PKU and a gene therapy approach for metachromatic leukodystrophy (MLD), Ho
Show less
Read more
Impact Snapshot
Event Time:
FIXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FIXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FIXX alerts
High impacting Homology Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
FIXX
News
- Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million [Yahoo! Finance]Yahoo! Finance
- Homology Medicines Declares Distribution to Common StockholdersGlobeNewswire
- Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law FirmGlobeNewswire
- HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXBusiness Wire
- Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases [Yahoo! Finance]Yahoo! Finance
FIXX
Earnings
- 11/14/23 - Miss
FIXX
Sec Filings
- 3/27/24 - Form 8-K
- 3/22/24 - Form 8-K/A
- 3/20/24 - Form 8-K
- FIXX's page on the SEC website